



2. LÉKAŘSKÁ FAKULTA
UNIVERZITA KARLOVA




**Univerzita
Karlova**

**FN
M+H** Fakultní
nemocnice
Motol a Homolka



Národní institut
virologie a bakteriologie

Seminar: *Brucella* and *Francisella*. Diagnostics of G-rods III


Jakub Hurych

Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University
& Motol and Homolka University Hospital

Microbiology I.
Practical sessions

Brucella and Francisella



Created by Daniela Lžičarová



Brucella

- The causative agent of brucellosis – a zoonosis; isolated imported cases in the Czech Republic; 500,000 cases worldwide per year
- Infection in cattle in the Czech Republic has been eradicated through rigorous veterinary control
- **Source of infection**
 - *Brucella abortus* – cattle, camels, yaks, bison
 - *Brucella melitensis* – goats, sheep, camels
 - *Brucella suis* – domestic pigs, wild boar, reindeer
 - *Brucella canis* – dogs





Route of transmission

- Contact of broken skin or the conjunctiva with tissues and body fluids of infected animals – **occupational infection**
- Consumption of raw, unpasteurised milk and dairy products
- Inhalation of infected aerosols
- Laboratory transmission

Human-to-human transmission is extremely rare, but has been reported (mother-to-child transmission, sexual transmission)

Incubation period usually **2–4 weeks**

Principles of diagnosis



- **1. Clinical presentation and medical history** – epidemiological (contact with animals)
- **2. Serology** (first-line laboratory method)
- **3. Confirmation** (culture/PCR)

Brucellosis – clinical presentation

A systemic disease that can affect any organ

Initially, non-specific symptoms typical of a systemic infection: **fever of unknown origin, joint/muscle pain, sweating**

Bang's disease, caused *by B. abortus* – chronic course, musculoskeletal system, typically sacroiliac joints, mortality 1–2%

Maltese fever, caused *by B. melitensis* – acute at onset, progresses to a chronic phase, frequent organ complications, mortality 5–10%

Brucellosis caused by B. suis – severe septic course, formation of abscesses in the liver, spleen and other organs, mortality 30%

Endocarditis

Risk **of relapse** following inadequate treatment, within 3–6 months

Treatment

Doxycycline + rifampicin, doxycycline + gentamicin, children: co-trimoxazole + rifampicin

Min. 6 weeks



Brucella melitensis, culture on
blood agar



Sukumaran ST, Thayyil SS, Ambramoli SK. Acute brucellosis caused by *Brucella melitensis*: A case report. J Acad Clin Microbiol 2013;15:66-8

Brucellosis – laboratory diagnosis


Serology

- **Agglutination, microagglutination** in acute cases; diagnosis is confirmed by a fourfold increase in titre when testing paired sera; a high titre in a single sample (dilution 1:160 or higher) is highly suspicious
- **ELISA**, indirect Coombs test, indirect immunofluorescence (IFA) – detection of non-agglutinating/incomplete antibodies in chronic and complicated cases

Direct detection

- **PCR** – tissue, serum, cerebrospinal fluid
- **Culture** – the gold standard, requires BSL-3 biosafety level
- Biological material – tissue, blood, cerebrospinal fluid, bone marrow, exudates (joint, pleural), abscess contents
- Culture media – blood culture bottle, solid enriched media (chocolate agar, media for detecting gonococci, brucella agar with horse blood), culture for 6 weeks, 37 °C, elevated CO₂ tension₂

Brucella melitensis, Gram stain



Sukumaran ST, Thayyil SS, Ambramoli SK. Acute brucellosis caused by *Brucella melitensis*: A case report. J Acad Clin Microbiol 2013;15:66-8

It's not always *Brucella*

- Haematological oncology patient
- Egypt: camel milk
- Blood culture: *Ochrobactrum* from MALDI

Folia Microbiologica (2025) 70:235–239
<https://doi.org/10.1007/s12223-024-01231-7>

ORIGINAL ARTICLE

Prolonged fever in a 13-year-old girl misdiagnosed as *Ochrobactrum* spp. bacteremia—the pitfalls of diagnostic *Brucella* spondylitis in a non-endemic country

Dita Smíšková¹ · Petr Smíšek² · Otakar Nyč³

Received: 5 August 2024 / Accepted: 28 November 2024 / Published online: 17 December 2024
© Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i. 2024

took a commercial cancer risk once.

A bone marrow examination revealed no haematological disease. Extensive microbiological examinations did not confirm any of the infectious diseases considered, the result of brucellosis serology was evaluated as negative according to the manufacturer's instructions. A polymorphic gram-negative bacillus was detected in blood culture taken on 14 August after two and a half days of incubation and identified as *Ochrobactrum* spp. by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) using Microflex LT/SH Smart in positive mode with MBT Compass 4.1.100 software including MALDI Biotyper library v.13–12,438 MSPs (Bruker Daltonics GmbH, Bremen, Germany). The result was evaluated at a score of 1.38–1.41. This very slowly growing bacteria in aerobic and anaerobic conditions was sensitive to cotrimoxazole, rifampicin, aminoglycosides, ciprofloxacin and tigecycline (based on the disc diffusion testing). The pathogen with the same characteristics was found in other cultures taken on 21 and 29 August.

PET-MRI, indicated to localise the focus of infection, showed spondylitis of the Th12 and L1 vertebral bodies. As spondylitis is a common complication of brucellosis, whereas *Ochrobactrum* spp causes it rarely, a re-evaluation of the agent was performed. Repeated serological testing (Latex agglutination in microtiter plate and Rose Bengal test) have already conclusively confirmed positive antibody titres. Additional use of archived spectrum—via MBT Compass Explorer v. 4.1.100 software with Database-CD BTyp2.0-Sec-Library 1.0 (referred to as “MBT SR – security relevant library”)—consists of 104 MSPs, clearly identified the pathogen as *B. melitensis* (score value 2.28).

Adequate antibiotic therapy (cotrimoxazole and gentamicin) was started after almost 4 months of clinical symptoms. Due to the patient's intolerance to i.v. therapy,

Table 1 Time line—key clinical and laboratory data

Date of medical examination	Main symptoms and results of laboratory and imaging tests
2023-05-18 GP	Fever up to 39 °C, sore throat. Treated with macrolide antibiotic for positive rapid strep test. Fever lasted 2 weeks, fatigue persisted
2023-06-01 GP	Fatigue, no fever – <i>leukopenia</i> (WBC $4.0 \times 10^9/L$), <i>anaemia</i> (HGB 103 g/L), <i>CRP</i> 12.9 mg/L (normal to 5.0 mg/L). <i>EBV</i> and <i>CMV</i> serology negative
2023-06-12 Emergency dpt	Recurrence of fever, new back pain in lumbar region. Back pain resolved after 5 days of analgesic therapy, fever lasted 10 days – <i>CRP</i> 26.0 mg/L. <i>Splenomegaly</i> of 158mm on abdominal and pelvic ultrasound. <i>Urinary tract infection</i> excluded
2023-06-27 GP	Recurrence of fever, lasted 10 days, fatigue – <i>leukopenia</i> (WBC $3.7 \times 10^9/L$), <i>CRP</i> 6.3 mg/L
2023-08-01 GP	Fever up to 40 °C for 5 days, fatigue, headache and sore throat. Body mass loss of 5 kg over 10 weeks, night sweats and transient swelling of right knee after increased activity. Referred to tertiary care centre – <i>Splenomegaly</i> , WBC $4.0 \times 10^9/L$, HGB 101 g/L, PLT $135 \times 10^9/L$, <i>CRP</i> 54.1 mg/L. <i>EBV</i> and <i>CMV</i> serology negative again. <i>Paranasal sinuses</i> and <i>chest X-rays</i> with normal results
2023-08-11 HOPD	Persistent fever above 38 °C, fatigue. Autoimmune diseases unlikely according to the specialist, use of non-steroidal anti-inflammatory drugs recommended. Travel history was completed – <i>CRP</i> (43 mg/L), <i>ESR</i> 35 mm/h, <i>anaemia</i> (HGB 98g/L). <i>Bone marrow aspiration</i> with signs of non-specific activation, no evidence of lymphoproliferative disease. <i>Leishmania</i> , <i>TBEV</i> , <i>Borrelia</i> , <i>Y. enterocolitica</i> , <i>F. tularensis</i> , <i>T. gondii</i> serology negative. <i>Brucella</i> antibodies titer 1:80 , evaluated as negative. <i>QuantiFERON TB Gold</i> negative
2023-08-21 HOPD	No fever for 7 days (on medication <i>Ibuprofen</i> 500 mg 3 t.d.) – Positive blood culture—<i>Ochrobactrum</i> spp. <i>Bacteria</i> confirmed in three blood cultures
2023-09-01	– <i>PET MRI</i> — <i>spondylitis</i> of Th12 and L1 vertebrae, no signs of <i>spondylodiscitis</i> and <i>paravertebral abscesses</i>
2023-09-04 IDD	<i>Spondylitis</i> therapy started, <i>Ochrobactrum</i> spp considered etiological agent. Due to the close relationship between <i>Brucella</i> spp. and <i>Ochrobactrum</i> spp., reevaluation of the agent was performed
2023-09-06 IDD	Antibiotic therapy for <i>Brucella</i> spondylitis initiated – <i>B. melitensis</i> antibodies titer 1:1280 , <i>B. abortus</i> 1:640 ; <i>B. suis</i> 1:640 , <i>Rose Bengal Test (RBT)</i> positive
2023-11-06	– <i>B. melitensis</i> antibodies titer 1:640
2023-11-28	ATB therapy finished after 12 weeks
2024-05-02	Patient has no clinical or laboratory evidence of disease relapse – <i>B. melitensis</i> antibodies titer 1:320. RBT positive

Brucellosis – sources

Jorgensen JF, Pfaller MA: Manual of Clinical Microbiology, 11th Edition, ASM Press 2015

Mandřáková Z. Brucellosis – basic information about the disease,
<http://www.szu.cz/tema/prevence/bruceloza-1>

Murray, PR. Medical microbiology, eighth edition, Elsevier 2016

Beneš J. Infectious Diseases, Galén Prague 2009

Brucellosis Reference Guide: Exposures, Testing, and Prevention. CDC 2017, www.cdc.gov

Francisella

Francisella tularensis

- in Europe, the *holarctica* subspecies (type B),
- in North America, the subspecies *tularensis* (A) – higher virulence than *holarctica*

Causative agent of tularemia, a zoonosis, a disease with natural foci


Highly dangerous agent (bioterrorism)

In the Czech Republic, there are approximately 50 cases per year

The main cause was widespread transmission among wild animals, particularly in brown hares and small rodents (field voles)



Veteriankey.com



Dr Kateřina Fabiánová, PhD, Department of Infectious Disease Epidemiology, CEM, SZÚ, Prague; July 2019, revised

***Francisella tularensis* – Central Europe**

Source of infection – wild mammals (rodents, lagomorphs, carnivores)

Transmission

- Contact with an infected animal, live or dead – broken skin, conjunctiva
- Vector – blood-sucking arthropods (*Ixodes*, *Dermacentor*)
- Inhalation of infectious aerosol
- Ingestion of infected water or food

▪ High risk of laboratory infection

- No human-to-human transmission has been reported

Very low infectious dose (10 organisms)
Incubation period 1–21 days



www.cdc.gov



absa.org



ecdc.europa.eu


Still from the Czech film *Vaterland*, 2004

Tularemia – pathogenesis

Intracellular survival and replication:
macrophages, neutrophils, epithelial
cells, endothelial cells

Inhibition of phagosome-lysosome
fusion

Polysaccharide capsule preventing
complement activation and
phagocytosis



Principles of diagnosis



- **1. Clinical presentation and medical history** – epidemiological (contact with animals)
- **2. Serology** (the laboratory method of first choice)
- **3. Confirmation** (culture/PCR)

Tularemia – clinical presentation

Always systemic symptoms (fever, fatigue, headaches, muscle and joint pain)

Clinical forms:

- **Ulceroglandular** – the most common
- Oculoglandular (infection enters via the conjunctiva)
- Glandular (lymphadenitis)
- Oropharyngeal (transmission via food)
- Pulmonary (aerosol transmission)
- Typhoid (systemic infection, unclear primary focus)

Type B – *holarctica* – minimal mortality, lower virulence; type A (*tularensis* – mortality 2% even with targeted treatment available)

Treatment: gentamicin, doxycycline, (ciprofloxacin, chloramphenicol)



Tularemia – laboratory diagnosis

A minimum of BSL-2/3 biosafety level is required for direct detection – only selected laboratories

Collection of biological material – direct detection

From the site of infection depending on the clinical form, after surface decontamination; liquid material, tissues (biopsy) and blood for haemoculture are most suitable (all clinical forms; risk of false negatives at the onset of infection)

If a swab is taken, then in transport medium

Rapid transport at room temperature; for longer transport, at 2–8 °C

Notify the laboratory in advance

For indirect detection (antibodies), collect 2 samples of clotted blood – the first as soon as possible after the onset of symptoms, the second 3–4 weeks later



absa.org



llnl.gov

Tularemia – laboratory diagnosis

Indirect detection – detection of antibodies from paired serum samples

- Agglutination (tube or micro-agglutination in a plate)
- ELISA + Western blot

Direct detection

- **PCR** – targeting specific *F. tularensis* genes, 16S (genus-specific)
- **Culture** – **only in** a **BSL-3** laboratory, **cysteine-enriched** media (from more common media, e.g. buffered charcoal yeast extract (BCYE) and GC Agar II with 1% haemoglobin and 1% IsoVitaleX) – aerobically for at least 48 hours at 37 °C.


F. tularensis can also grow from tissue or fluid samples on standard media (blood or chocolate agar...) and in haemoculture flasks – caution is required!

- **Antigen detection** (using a fluorescently labelled antibody directly in the material)


Identification: MALDI-TOF

Microscopy of minimal significance; easily overlooked in clinical material, but weakly G-stains; morphologically very small G-cocobacilli – smaller than *Haemophilus*

***Francisella tularensis* – Gram stain**




***Francisella tularensis* - cultivation**



- (A) buffered charcoal yeast extract;
- (B) chocolate agar medium;
- (C) sheep's blood agar;
- (D) cysteine heart agar.

Pathogen profile dictionary
ppdictionary.com

Tularemia – detection of antibodies by agglutination reaction



Tularemia – sources:

Jorgensen JF, Pfaller MA: Manual of Clinical Microbiology, 11th Edition, ASM Press 2015

Fabiánová K. et al. Tularemia – basic information, SZÚ website
<http://www.szu.cz/tema/prevence/tularemie-zakladni-informace>


Tärnvik A et al. WHO Guidelines on Tularaemia, WHO 2007

Carvalho CL et al. Tularaemia: A challenging zoonosis. **Comparative Immunology, Microbiology and Infectious Diseases**, Volume 37, Issue 2, March 2014, Pages 85–96
<https://doi.org/10.1016/j.cimid.2014.01.002>

Diagnostics of G-bacteria III

Fastidious bacteria

Created by Anežka Gryndlerová



Contents

- *Neisseria sp.*
- *Haemophilus sp.*
- *Bordetella sp.*
- *Legionella pneumophila*

- *Moraxella catarrhalis*

Neisserie



Neisseria spp.

Protokol: X-23-2423 --- Konečný výsledek ---
Vzorek: Aspirát DCD endotracheální (ET)
Vyšetření: DCD - kultivace

MIKROSKOPICKY

Preparát z klinického materiálu: buněčná drť, řasinkové epitelie, leukocyty 10-25, g+koky , g-tyčinky zcela ojediněle

PRIMOKULTIVACE

Nález 1: *Klebsiella pneumoniae*

Nález 2: *Neisseria subflava*

- G-aerobic diplococci, **coffee bean-shaped**
- Representatives?
 - *Neisseria gonorrhoeae* (gonococcus)
 - *Neisseria meningitidis* (meningococcus)
 - *Neisseria subflava*, *flavescens*, *perflava*, ...
 - Common microbiota of the oral cavity and HCD
- Sensitive to environmental influences, difficult to culture
 - ?
 - *N. gonorrhoeae*, *meningitidis*

Neisseria gonorrhoeae – the disease

- Gonorrhoea
 - Urethritis, cervicitis – whitish discharge
 - Epididymitis, prostatitis, salpingitis
 - Anorectal gonorrhoea, tonsillopharyngitis
- Pelvic inflammatory disease (PID)
 - Involvement of the pelvic organs (uterus, adnexa)

Gonorrhoea – diagnosis

- Sample collection?
 - Urine (first sample), cervical swab, urethral swab
 - Throat swab, rectal swab
- Transport of samples
- Culture (CA, selective enriched agar)
 - MALDI-TOF (*Neisseria sp.*) → biochemical analysis (species identification)
- PCR



NEISSERIA test									Dodatkové testy		
Jamka:	H	G	F	E	D	C	B	A			Thayer- Martinův agar
Test:	NEC	GLU	MLT	FRU	SUC	GGT	TRB	SPS	ONP	DNA	
N. gonorrhoeae	–	+	–	–	–	–	–	–	–	–	+
N. meningitidis	–	+	+	–	–	+	–	–	–	–	+
N. lactamica	–	+	+	–	–	–	–	–	+	–	+
N. polysaccharea	–	+	+	–	d	–	–	+	–	–	+
N. sicca+	–	+	+	+	+	d	–	+	–	–	–
N. mucosa+											
N. subflava	–	+	+	d	d	d	–	d	–	–	–
N. flavescens	–	–	–	–	–	–	–	+	–	–	–
N. cinerea++	–	–	–	–	–	–	–	–	–	–	–
N. elongata++											
M. (B.) catarrhalis	–	–	–	–	–	–	+	–	–	+	–



MT-PCR Sample Report - Sample 25225775


No.	Colour	Gene	Call	Concentration	Corrected Melt	Take-off
I1	■	Chlamydia				
I2	■	LGV				
I3	■	Gonorrhoeae	Present (opaJ, opaH)	759 749	80,03 88,49	12,17
I4	■	RUO: Ceftriaxone R				
I5	■	T.vaginalis				
I6	■	U.urealyticum				
I7	■	M.hom, U.parvum				
I8	■	M.genitalium				
I9	■	Fluoroquinolone R				
I10	■	Mgen 23S				
I11	■	Human DNA	Present	5 178 849	84,53	9,18
I12	■	SPIKE	Present	50 000	81,8	18,41

Operator: MA, Sample Volume: 10µl, Step 1 Sensitivity: NA extract or swab (18 cycles), Analysis Sensitivity: Normal


MasterMix cartridge batch: C264550DL, Step 1 reaction tube batch: S2654311

File: I:\1567 - Urinogenital and Resistance 12 well 2022-12-15 1429.epx

Cycling Curves



Melt Curves



Protokol: LMM-22-3972

--- Konečný výsledek ---

Vzorek: Výtěr z pochvy

Vyšetření: PCR STD

Sexuálně přenosné choroby - vyšetření metodou PCR

(V závorce uvedena relativní kvantita nabývající hodnot od * [nejmenší] do ***** [největší])

Chlamydia trachomatis: negativní

Neisseria gonorrhoeae: POZITIVNÍ (*****)

Mycoplasma genitalium: negativní

Mycoplasma hominis: POZITIVNÍ

Ureaplasma parvum: POZITIVNÍ

Pozn. Při současné pozitivě *M. hominis* a *U. parvum* systém neumožňuje každý z nálezů odděleně kvantifikovat. Pozitivita agens s vyšší kvantitou (nelze říci, o které z těchto dvou se jedná) je: *****

Ureaplasma urealyticum: negativní

Trichomonas vaginalis: negativní

Telefonické hlášení:

12.09.2022-14:14 MUDr. Kelčík Roland

Mgr. Dratvová Barbora

PCR pozitivita *N.gonorrhoeae*, *M. hominis* a *U. parvum*.

Protokol: K-23-4015 --- Konečný výsledek ---
Vzorek: Výtěr z krku
Vyšetření: HCD - kultivace

PRIMOKULTIVACE

Nález 1: viridující streptokoky, neisserie

Protokol: K-23-1088 --- Konečný výsledek ---
Vzorek: Výtěr z krku
Vyšetření: HCD - kultivace, Neisseria gonorrhoeae - kultivace

PRIMOKULTIVACE

Nález 1: viridující streptokoky, neisserie

Kultivace cílená na Neisseria gonorrhoeae

Nález: negativní

Kódy pro pojišťovnu: 82017(1), 82025(1), 82031(1)

- 
- Testing for gonorrhoea from the throat or rectum – special request

Neisseria gonorrhoeae – the disease

- Disseminated gonococcal infection
 - Purulent arthritis
 - Maculopapular rash
 - Rarely, sepsis, meningitis
 - (Specimen collection: blood culture, joint aspirate)
- Neonatal conjunctivitis
 - Conjunctival swab
 - Prevention – disinfectant solution



Therap y

- Beta-lactams
 - Basic penicillins – frequently resistant (beta-lactamase)
 - Third-generation cephalosporins
- Alternatives (but more frequent resistance)
 - Tetracyclines
 - Macrolides
 - Fluoroquinolones

Neisseria meningitidis

- Colonisation of the pharyngeal mucosa
- Polysaccharide capsule
 - Serotypes - ?
 - A
 - B
 - C
 - W135
 - Y

Neisseria meningitidis – disease

- Invasive meningococcal disease (IMD)
 - Preceded by flu-like symptoms (fever, headache, muscle pain, nausea, vomiting)
 - Sepsis
 - Purulent meningitis
 - Mixed form
- Lipooligosaccharide – endotoxin
 - Sepsis
 - DIC (disseminated intravascular coagulation)
- Incidence: mainly children under 2 years of age, adolescents



Neisseria meningitidis – diagnosis

- Sample collection?
 - cerebrospinal fluid, blood culture, necrotic tissue
- Microscopy
- Culture (CA, KA)
 - MALDI-TOF (*Neisseria sp.*) → biochemical analysis (species identification)
- PCR (cerebrospinal fluid)

Meningitidy - PCR statim

Escherichia coli: negativní

Haemophilus influenzae: negativní

Listeria monocytogenes: negativní

Neisseria meningitidis: POZITIVNÍ

Streptococcus agalactiae: negativní

Streptococcus pneumoniae: negativní

Neisseria meningitidis – treatment

- Third-generation cephalosporins (immediately), penicillin G
- Prevention – vaccination (optional)
 - A, C, W135, Y
 - B

Haemophiliacs

Haemophilus spp.

- Commensals of the oral cavity and pharynx
- Difficult to culture
 - Sensitivity to external factors
 - Nutritional requirements
 - factor V (NAD), factor X (hemin)
- Representatives - ?
 - *Haemophilus influenzae*
 - *Haemophilus parainfluenzae*
 - *Haemophilus haemolyticus*
 - *Haemophilus ducreyi* (chancroid)

Protokol: HEM-23-3089 --- Konečný výsledek ---
Vzorek: Aspirát DCD fibroaspirát
Vyšetření: DCD - kultivace

MIKROSKOPICKY

Preparát z klinického materiálu: buněčná drť, erytrocyty, dlaždicové epitellie, g+koky

PRIMOKULTIVACE

Nález 1: viridující streptokoky, neisserie

Nález 2: *Rothia mucilaginosa*
(g+ koky ve dvojicích a tetrádách, fyziologická součást mikroflóry orofaryngu)

POMNOŽENÍ

Nález: dtto

Mikroaerofilní kultivace

Nález : *Haemophilus parahaemolyticus*

Screening na kvasinky a plísně

Nález: negativní

Výsledek prodloužené mykologické kultivace sdělíme v případě positivity dodatečně - celková délka kultivace je 5 dní.



Haemophilus influenzae


- G- (very) short rods, facultative anaerobes
- Polysaccharide capsule (some strains)
 - a-f
 - Subtype b
- Origin of the species name?

Haemophilus influenzae – a disease?

- HCD infection
 - Otitis media, sinusitis
 - Epiglottitis
- Pneumonia
- Conjunctivitis
- Meningitis

Haemophilus influenzae – diagnosis?


- HDC infection
 - Otitis media, sinusitis
 - Epiglottitis
- Pneumonia
- Conjunctivitis
- Meningitis



- puncture fluid, pus,
(swab)

Haemophilus influenzae – diagnosis?


- HDC infection
 - Otitis media, sinusitis
 - **Epiglottitis**
- Pneumonia
- Conjunctivitis
- Meningitis



- blood culture

Haemophilus influenzae – diagnosis?

- HDC infection
 - Otitis media, sinusitis
 - Epiglottitis
- Pneumonia
- Conjunctivitis
- Meningitis




- sputum, blood culture, ~~throat swab~~



Haemophilus influenzae – diagnosis?


- HDC infection
 - Otitis media, sinusitis
 - Epiglottitis
- Pneumonia
- **Conjunctivitis**
- Meningitis



- Conjunctival
swab

Haemophilus influenzae – diagnosis?

- HDC infection
 - Otitis media, sinusitis
 - Epiglottitis
- Pneumonia
- Conjunctivitis
- **Meningitis**



- Cerebrospinal fluid, blood
culture

Haemophilus influenzae – diagnosis

- Culture
 - CA, KA with staphylococcal streak – **satellite phenomenon**
- CSF
 - Culture + microscopy, PCR

- The next 5 most common causes of bacterial meningitis?

Protokol: LMM-23-2027 --- Konečný výsledek ---
Vzorek: Likvor z lumbální punkce
Vyšetření: Bakteriální meningitidy - PCR

Neuroinfekce - vyšetření metodou PCR

Streptococcus pneumoniae: negativní


Haemophilus influenzae: negativní

Neisseria meningitidis: negativní

Listeria monocytogenes: negativní

Escherichia coli: negativní

Streptococcus agalactiae: negativní



H. influenzae – resistance to beta-lactams

- Beta-lactamase (primary penicillins, aminopenicillins)
 - Other resistance mechanisms (mutations in the PBP gene)

Nález 1: *Haemophilus influenzae*

ANTIBIOGRAM (disková difuzní metoda)

ampicilin.....	C	tetracyklin.....	C
amoxicilin /klavulanát...	C	nalidixová kyselina.....	C
cefuroxim.....	C	chloramfenikol.....	C
cefotaxim.....	C	kotrimoxazol.....	C

Nález 1: *Haemophilus influenzae*

ANTIBIOGRAM (disková difuzní metoda)

ampicilin.....	R	nalidixová kyselina.....	C
cefuroxim.....	C	chloramfenikol.....	C
cefotaxim.....	C	kotrimoxazol.....	C
tetracyklin.....	C		

ANTIBIOGRAM - MIC v mg/l (E-test)

ampicilin /sulbactam.....	1	C	cefotaxim.....	0,023	C
---------------------------	---	---	----------------	-------	---

Nález 2: *Haemophilus influenzae*

ANTIBIOGRAM (disková difuzní metoda)

ampicilin.....	R	tetracyklin.....	C
amoxicilin /klavulanát...	R	nalidixová kyselina.....	C
cefuroxim.....	R	chloramfenikol.....	C
cefotaxim.....	C	kotrimoxazol.....	R

H. influenzae – treatment

- Meningitis, epiglottitis
 - Third-generation cephalosporins
- Aminopenicillins, extended-spectrum aminopenicillins
- Prevention – vaccination (Hib – hexavalent vaccine)

od začátku 9. týdne (2 měsíce)	Záškrt, tetanus, černý kašel, dětská obrna, virová hepatitida B, onemocnění vyvolaná Haemophilus influenzae b
2.–3. měsíc	
4 měsíce	Záškrt, tetanus, černý kašel, dětská obrna, virová hepatitida B, onemocnění vyvolaná Haemophilus influenzae b
4.–6. měsíc	
11.–13. měsíc	Záškrt, tetanus, černý kašel, dětská obrna, virová hepatitida B, onemocnění vyvolaná Haemophilus influenzae b
12.–15. měsíc	
13.–18. měsíc	Spalničky, zarděnky, příušnice
od dovršení 5. do dovršení 6. roku věku dítěte	Spalničky, zarděnky, příušnice
	Záškrt, tetanus, černý kašel
od dovršení 10. do dovršení 11. roku	Záškrt, tetanus, černý kašel, dětská obrna

The HACEK Group

- G-negative rods, microbiota of the lower respiratory tract and pharynx
- Less common causes of infective endocarditis
- *Haemophilus spp.*
- *Aggregatibacter spp.*
- *Cardiobacterium spp.*
- *Eikenella corrodens*
- *Kingella kingae*



- + osteomyelitis - infants, toddlers

<https://microbiologycanadas.com/Bacteria/gram-negative-rods/facultative-anaerobic-3/no-growth-on-mcconkey-agar-without-salt-1/catalase-negative-3/oxidase-positive-5/eikenella-corrodens.html>

Bordetella

Bordetella


- G-aerobic rods
- Extremely sensitive to drying, toxins and toxic substances
- Representatives?
 - *Bordetella pertussis*
 - *Bordetella parapertussis*

B. pertussis – virulence factors (examples)

- Filamentous haemagglutinin, pertactin, fimbriae
 - Adhesion factors
- Pertussis toxin
 - Influence on the immune response, leukocytosis with lymphocytosis, ...
- → Contained in vaccines

Bordetella pertussis

- Pertussis – whooping cough
 - At-risk population – infants
 - Catarrhal stage
 - Paroxysmal stage
 - <https://www.youtube.com/watch?v=S3oZrMGDMMw>
 - Convalescent stage
- Atypical course
 - Other age groups



<https://www.cdc.gov/pertussis/about/signs-symptoms.html>

Bordetella pertussis – diagnosis

- Sample collection
 - material from the lower respiratory tract (sputum),
nasopharyngeal swab
 - ~~Blood culture~~ (non-invasive)
- Cultivation
 - First stage of the disease
 - Extended culture (5 days), Bordet-Gengou agar and others
- PCR (higher sensitivity)
- Serology
 - Antibodies against pertussis toxin



Protokol: SER-23-1143

--- Konečný výsledek ---

Vzorek: Sérum

Vyšetření: Bordetella pertussis - protilátky , Bordetella parapertussis - protilátky, Mycoplasma pneumoniae - protilátky, Chlamydia pneumoniae - protilátky, Chlamydia pneumoniae - konfirmace, Chlamydia trachomatis - protilátky, Chlamydia trachomatis - konfirmace, Stáčení séra

Chlamydia trachomatis screening

Chlamydia trachomatis IgA: negativní

Chlamydia trachomatis IgG: negativní

Chlamydia trachomatis West.Blot IgA: negativní

Chlamydia trachomatis West.Blot IgG: negativní

Chlamydia pneumoniae (ELISA)

Chlamydia pneumoniae IgA: 73,26 U/ml - POZITIVNÍ

Chlamydia pneumoniae IgG: >320 U/ml - POZITIVNÍ

Chlam. pneum. West.Blot IgA: hraniční

Chlam. pneum. West.Blot IgG: POZITIVNÍ

Mycoplasma pneumoniae (ELISA)

Mycoplasma pneumoniae IgM: negativní

Mycoplasma pneumoniae IgG: negativní

Pertusse toxin

Pertusse toxin IgA: 19,5 IU/ml - POZITIVNÍ

Pertusse toxin IgG: negativní

Parapertusse

Bordetella parapertussis IgA: negativní

Bordetella parapertussis IgG: 3,05 index - POZITIVNÍ

Závěrečné hodnocení:

Chlamydia pneumoniae - nejspíše se jedná o postakutní fázi infekce nebo anamnestické protilátky, k potvrzení výsledku doporučuji kontrolní vyšetření za 2-3 týdny.

Pertuse toxin - k rozlišení počáteční fáze infekce a nespecifické aktivace IgA protilátek je nutné vyšetření párového séra v odstupu cca 10 - 14 dní.

Parapertuse - nejspíše se jedná o anamnestické protilátky, k potvrzení doporučuji kontrolní vyšetření párového séra v odstupu cca 10 - 14 dní.

Bordetella pertussis – treatment

- Macrolides – good penetration into the mucous membranes
- Catarrhal phase – greatest effect
- Prevention – vaccination
 - Hexavalent vaccine
 - Pertussis toxoid, filamentous haemagglutinin, pertactin
 - (+ fimbriae antigens)
 - 3rd trimester of pregnancy

od začátku 9. týdne (2 měsíce)	Záškrt, tetanus, černý kašel, dětská obrna, virová hepatitida B, onemocnění vyvolaná Haemophilus influenzae b
2.–3. měsíc	
4 měsíce	Záškrt, tetanus, černý kašel, dětská obrna, virová hepatitida B, onemocnění vyvolaná Haemophilus influenzae b
4.–6. měsíc	
11.–13. měsíc	Záškrt, tetanus, černý kašel, dětská obrna, virová hepatitida B, onemocnění vyvolaná Haemophilus influenzae b
12.–15. měsíc	
13.–18. měsíc	Spalničky, zarděnky, příušnice
od dovršení 5. do dovršení 6. roku věku dítěte	Spalničky, zarděnky, příušnice
	Záškrt, tetanus, černý kašel
od dovršení 10. do dovršení 11. roku	Záškrt, tetanus, černý kašel, dětská obrna

Bordetella pertussis

- <https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/tdap-vaccine-pregnancy.html>

These first few months of life are when infants are at the greatest risk of contracting pertussis and having severe, potentially life-threatening complications from the infection. To help protect babies during this time when they are most vulnerable, women should get the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) during **each** pregnancy. A strong recommendation from you may be what most influences whether or not your patient's newborn is protected against pertussis.

5 Facts about Tdap and Pregnancy

1. **Tdap during pregnancy provides the best protection for mother and infant.**
 - Recommend and administer or refer your patients to receive Tdap during every pregnancy.
 - Optimal timing is between 27 and 36 weeks gestation (preferably during the earlier part of this period) to maximize the maternal antibody response and passive antibody transfer to the infant.
 - Fewer babies will be hospitalized for and die from pertussis when Tdap is given during pregnancy rather than during the postpartum period.

B. parapertussis

- Disease
 - parapertussis, pertussis-like syndrome
- Does not produce pertussis toxin
- Cannot be prevented by vaccination

Legionella pneumophila

Legionella pneumophila

- Origin of the name?
- G-aerobic rods
- Pontiac fever
 - Flu-like symptoms
- Legionnaires' disease
 - Severe 'atypical' pneumonia
- At-risk groups
 - Elderly people, immunocompromised individuals



Legionella pneumophila – diagnosis

- Sample collection
 - Sample from the DDC
 - Nasopharyngeal swab (PCR)
 - Urine
- Culture
 - 5 days, enriched media
- PCR
- Ag testing of urine (type 1)
- → macrolides,
fluoroquinolones



Protokol: LMM-23-2099

--- Konečný výsledek ---

Vzorek: Výtěr z nazofaryngu

Vyšetření: atypické pneumonie - PCR

Atypické pneumonie - vyšetření metodou PCR

(V závorce uvedena relativní kvantita nabývající hodnot od * [nejmenší] do ***** [největší])

Mycoplasma pneumoniae: negativní

Chlamydophila pneumoniae: negativní

Chlamydophila psittaci: negativní

Legionella pneumophila: negativní

Legionella longbeachae: negativní

Pneumocystis jiroveci: negativní

Cryptococcus neoformans: negativní

Závěrečné hodnocení:

Upozornění: Pro správnou interpretaci nálezu je vhodné pamatovat na to, že byl v tomto případě **vyšetřen materiál z horních cest dýchacích** (HCD). **Pozitivní výsledek** může často znamenat přítomnost daného agens i v dolních cestách dýchacích (DCD), ale někdy jen pouhou kolonizaci HCD (př. *Pneumocystis*). **Negativní výsledek** zcela nevylučuje možnou přítomnost daného agens v DCD (př. *Legionella*). V takovém případě (při klinickém obrazu svědčícím pro atypickou pneumonii) doporučujeme výsledek verifikovat vyšetřením vzorku odebraného z DCD.

Moraxella catarrhalis

Formerly *Branhamella catarrhalis*

Moraxella catarrhalis

- G-aerobic diplococcus
- Commensal of the mucous membranes of the upper respiratory tract
- Sinusitis, otitis
- Potentiated aminopenicillins
 - Beta-lactamase
- Colonies can be 'moved' on agar

Summary

- *Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae, Bordetella pertussis, Legionella pneumophila*
- The above-mentioned pathogens can be cultured in routine clinical practice. However, this often requires special enriched media and the culture takes longer (compared to, for example, staphylococci, enterobacteria, etc.).
- PCR can be used to diagnose the above-mentioned pathogens (depending on the sample taken and the microorganism detected)
- In some cases, serological testing for antibodies (pertussis) can be performed.